Compare Microsoft (MSFT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Neurocrine Biosciences Inc — how do they compare? Microsoft trades at $501.64 (market cap $3.76T), while Neurocrine Biosciences Inc trades at $162.07 (market cap $16.76B). The key difference: Microsoft is far larger — about 224.3× Neurocrine Biosciences Inc's market cap, and Microsoft pays a 0.72% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MSFT | NBIX | |
|---|---|---|
Market Cap | $3.76T | $16.76B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $185.50 |
52-Week Low | $352.83 | $123.10 |
Enterprise Value | $3.74T | $16.78B |
Dividend Yield | 0.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $506.06, up 1.21% today, near its pivot point of $507. The stock shows strong bullish momentum with consistent earnings beats, including Q2 2026 EPS of $4.74 versus $4.24 expected. Revenue growth accelerated to $281.72B in 2025, with a net income margin of 40.31%. Analysts maintain an 80.49% buy rating, citing AI leadership via Azure and Copilot.
Outlook remains positive with a consensus price target of $553.70, though risks include high capital expenditures and competitive pressures in AI. The stock's valuation multiples like P/E of 28.19 are elevated, requiring sustained execution. Near-term support lies at $500, with resistance at $513.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
